Acute And Subacute Skin Manifestations Of Systemic Lupus Erythematosus Are Associated With An Earlier Response To Belimumab Than The Chronic Phenotype: Preliminary Data From The New Nation-Wide Cohort Of Belimumab In Real Life Setting Study—New Joint And Skin (BERLISS-NEJS)

The study analyzed 312 systemic lupus erythematosus (SLE) patients treated with belimumab, focusing on different skin and joint manifestations. Results showed that belimumab was effective in reducing disease activity across various joint and skin phenotypes, with significant improvements in DAS28, SRI-4, and SLEDAI-2K scores. Notably, patients with acute and subacute skin manifestations responded earlier to belimumab compared to those with chronic skin phenotypes. However, no significant response was observed in patients with SLE-nonspecific skin manifestations alone. The study highlights the differential response to belimumab based on specific skin phenotypes in SLE patients.